CCRP Therapeutics

Executive Summary

CCRP Therapeutics is a German biopharmaceutical company (founded 2019 as a Charité spin-off) developing a novel class of small molecule drugs targeting the renin/prorenin receptor (RERB). The company's approach addresses critical pathways underlying oncology and end-organ damage, with initial programs in colorectal cancer, hepatocellular carcinoma, pancreatic cancer, sarcoma, and complications from diabetes and hypertension. By blocking the prorenin receptor, CCRP aims to inhibit downstream signaling that drives tumor growth and fibrosis.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead RERB Candidate60% success
• Q4 2026Publication of Preclinical Proof-of-Concept Data70% success
• Q1 2026Series A Financing or Strategic Partnership50% success